Galmed Pharmaceuticals (GLMD) Cash & Current Investments (2013 - 2026)

Galmed Pharmaceuticals' Cash & Current Investments history runs 14 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 2.55% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $11.9 million (down 2.55% YoY), while the FY2025 annual figure was $11.0 million, up 42.06% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $11.9 million, up from $11.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $28.7 million in Q1 2022, with the low at $2.1 million in Q4 2024.
• The 5-year median for Cash & Current Investments is $12.0 million (2023), against an average of $13.4 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments sank 80.1% in 2024, then soared 432.66% in 2025.
• Galmed Pharmaceuticals' Cash & Current Investments stood at $13.8 million in 2022, then dropped by 24.64% to $10.4 million in 2023, then tumbled by 80.1% to $2.1 million in 2024, then jumped by 432.66% to $11.0 million in 2025, then rose by 7.9% to $11.9 million in 2026.
• Business Quant data shows GLMD's Cash & Current Investments at $11.9 million in Q1 2026, $11.0 million in Q4 2025, and $13.0 million in Q3 2025.